Navigation Links
Watson Confirms Court Decision Rejecting Teva's Motion to Prevent Launch of Generic SEASONIQUE®
Date:6/17/2011

n-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages;  the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended March 31, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors:Patty Eisenhaur(862) 261-8141Media:Charlie Mayr(862) 261-8030
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watsons Nabumetone Tablets Receive FDA Approval
2. Watson Confirms Pataday™ Patent Challenge
3. Watson Confirms Viagra® Patent Challenge
4. Watson to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference
5. Watson Launches Generic AMRIX®
6. Watson Launches Generic Concerta®
7. Watson Pharmaceuticals to Webcast Annual Meeting of Stockholders on May 13th
8. Watson First Quarter 2011 Net Revenue Increases to $877 Million
9. New Life Agency Adds Watson to Join Walgreens on The Fertility Pharmacy Care Card for Fertility Medication
10. Watson Confirms Welchol® Patent Challenge
11. Columbia Laboratories and Watson Announce Publication of Positive Phase III PROCHIEVE® Vaginal Progesterone Gel Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... R.I. , Jan. 15, 2014 MultiCell Technologies, ... filed a U.S. provisional patent application concerning composition of ... to achieve targeted tumor cell death.  ... small noncoding double stranded RNA molecules (VSRNAs) which interfere ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... May 19, 2007 /PRNewswire/ -- Data presented,today at ... mg tablets administered once-daily for five days is ... for 10,days for the treatment of complicated urinary ... Inc., the company that markets LEVAQUIN in the,U.S., ...
... 19, 2007 - King,Pharmaceuticals, Inc. (NYSE:KG) reported ... trial evaluating Altace (ramipril) 20mg and the,combination ... were,presented this weekend at the American Society ... and Exposition,(ASH 2007) in Chicago, Illinois. The ...
Cached Medicine Technology:Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 2King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 3King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 4King Pharmaceuticals Reports Efficacy of Altace 20mg And Efficacy,of a Combination of Altace 20mg And Hydrochlorothiazide 25mg For,24-hour Blood Pressure Control 5
(Date:4/18/2014)... Johns Hopkins University School of Medicine researchers have been ... for diabetes, Novo Nordisk announced this month. Of the ... and Obesity Biologics Science Forum Program, only four projects ... Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. ... , Jonathan Powell, a professor of oncology, will use ...
(Date:4/18/2014)... French . ... medicine. A team led by Ludwik Leibler from the ... Didier Letourneur from the Laboratoire Recherche Vasculaire Translationnelle (INSERM/Universits ... the principle of adhesion by aqueous solutions of nanoparticles ... and tissues. This easy-to-use gluing method has been tested ...
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... Pen ... Technology, ... system, a new innovative solution for,digitally capturing patient information that is ... administer. The Docuscan Patient History solution with Paros(TM) technology enables,digital ...
... pop stars are more than twice as likely as the ... within a few years of becoming famous, reveals research published ... Health. , The findings are based on more than 1050 ... fame between 1956 and 1999. , All the musicians featured ...
... Steps for Young Children Program, which added behavior ... benefit families more than two years after the ... from the Johns Hopkins Bloomberg School of Public ... Steps included greater satisfaction among parents with their ...
... give rise to exuberant scarring, which can lead to ... disfigurement. In a review article in this weeks PLoS ... of Medicine) and colleagues examine the process of such ... the research areas that are likely to lead to ...
... ARLINGTON, Va., Aug. 22 The American,Psychiatric Association (APA) ... review of scientific evidence that led to the,approval of ... The APA is pleased that the approvals are a ... which was designed to,encourage research that leads to this ...
... safety of blood supply by detecting virus ... earlier in infection cycle., ... & Drug Administration (FDA) today approved its biologics,license application for the ... blood and plasma. West Nile virus, which can,cause serious health issues, ...
Cached Medicine News:Health News:New 'Smart' Technology Makes Patient Data Collection Easier, More Efficient 2Health News:Pop stars more than twice as likely to die an early death 2Health News:Practice-based intervention has sustained benefits for children and families 2Health News:APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder 2Health News:FDA Approves New Roche West Nile Virus Blood Screening Test 2Health News:FDA Approves New Roche West Nile Virus Blood Screening Test 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: